Premium
Review of biologics in allergic contact dermatitis
Author(s) -
Bhatia Jushya,
Sarin Ankur,
Wollina Uwe,
Lotti Torello,
Navarini Alexander A.,
Mueller Simon M.,
Grabbe Stephan,
Saloga Joachim,
Rokni Ghasem R.,
Goldust Mohamad
Publication year - 2020
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1111/cod.13584
Subject(s) - medicine , secukinumab , infliximab , dermatology , omalizumab , dupilumab , adalimumab , etanercept , allergic contact dermatitis , ustekinumab , efalizumab , immunology , allergy , atopic dermatitis , psoriasis , tumor necrosis factor alpha , immunoglobulin e , antibody , psoriatic arthritis
The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes its management challenging. With advances in the understanding of the cellular and molecular pathogenesis of ACD, newer therapeutic targets are becoming apparent. In particular, the use of biologics has gained momentum, given the specificity of their action. This article aims to review the presently available data on the use of biologics in ACD. English‐language–based literature available on the use of biological therapy was thoroughly probed in the following databases as on October 14, 2019: PubMed, Google Scholar, The Cochrane library, Embase, Scopus, and EBSCO. The following keywords were used: “contact dermatitis”, “allergens”, “delayed‐type hypersensitivity reaction”, “biologics”, “biological therapy”, “monoclonal antibodies”, “patch testing”, “TNF‐α inhibitors”, “infliximab”, “adalimumab”, “etanercept”, “dupilumab”, “omalizumab”, “secukinumab”, “ustekinumab”, “rituximab”.